# Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia

> **NCT03009240** · PHASE1 · COMPLETED · sponsor: **City of Hope Medical Center** · enrollment: 12 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Secondary Acute Myeloid Leukemia
- Therapy-Related Acute Myeloid Leukemia
- Untreated Adult Acute Myeloid Leukemia

## Interventions

- **DRUG:** Decitabine
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Pevonedistat
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT03009240
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-21
- **Primary completion:** 2026-03-19
- **Final completion:** 2026-03-19
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2026-04-22

## Collaborators

- National Cancer Institute (NCI)

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03009240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03009240, "Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT03009240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*